A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

Cell Death and Disease

Volumn 1, Issue 5, 2010, Pages

  Placzek, W J ^a   Wei, J ^a   Kitada, S ^a   Zhai, D ^a   Reed, J C ^a   Pellecchia, M ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Bcl 2; Bfl 1; Cancer therapeutics; Expression; Mcl 1

Indexed keywords

BCL2 RELATED PROTEIN A1; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; PUMA PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CELL CULTURE; CELL DEATH; COLON CANCER; DNA DAMAGE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MELANOMA; NONHUMAN; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; TUMOR CELL LINE; BIOLOGICAL MODEL; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENCE POLARIZATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR LIBRARY; NEOPLASM; TREATMENT OUTCOME;

APOPTOSIS; CELL LINE, TUMOR; FLUORESCENCE POLARIZATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SMALL MOLECULE LIBRARIES; TREATMENT OUTCOME;

EID: 79953719297     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2010.18     Document Type: Article

References (40)

1. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-2953. (Pubitemid 29415256)
2. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326. (Pubitemid 28406819)
3. Liang H, Fesik SW. Three-dimensional structures of proteins involved in programmed cell death. J Mol Biol 1997;274:291-302. (Pubitemid 27520618)
4. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-629. (Pubitemid 39006738)
5. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885. (Pubitemid 41746032)
6. Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K et al. Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 2001;98:3012-3017. (Pubitemid 32220791)
7. Rochaix P, Krajewski S, Reed JC, Bonnet F, Voigt JJ, Brousset P. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 1999;187:410-415. (Pubitemid 29118271)
8. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Pötter R, Jansen B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998;8:197-203. (Pubitemid 28313756)
9. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J et al. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 1999;67:763-768.
10. Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 2007;67:4564-4571. (Pubitemid 46910160)
11. Maruyama R, Yamana K, Itoi T, Hara N, Bilim V, Nishiyama T et al. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer 2006;95:1244-1249. (Pubitemid 44658490)
12. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944. (Pubitemid 23006303)
13. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995;55:735-738.
14. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576. (Pubitemid 26135897)
15. Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, Bloemena E et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 2001;12:779-785. (Pubitemid 32655086)
16. Kouraklis G, Kakisis J, Theoharis S, Tzonou A, Glinavou A, Raftopoulos J et al. Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer. Dig Dis Sci 2003;48:2284-2289. (Pubitemid 38021732)
17. Shigemasa K, Katoh O, Shiroyama Y, Mihara S, Mukai K, Nagai N et al. Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn J Cancer Res 2002;93:542-550. (Pubitemid 34752911)
18. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003;89:55-64. (Pubitemid 36897935)
19. Kitada S, Reed JC. MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. J Natl Cancer Inst 2004;96:642-643. (Pubitemid 38660217)
20. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent upregulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403-4413.
21. Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG et al. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 1998;47:129-140. (Pubitemid 28046084)
22. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE. Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 2009;7:549-556.
23. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 2007;26:5828-5832. (Pubitemid 47312815)
24. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
25. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-5929. (Pubitemid 29399297)
26. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681. (Pubitemid 40825512)
27. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001;117:333-340. (Pubitemid 34205719)
28. Wolter KG, Verhaegen M, Fernandez Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 2007;14:1605-1616. (Pubitemid 47278846)
29. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13:1419-1421. (Pubitemid 44057478)
30. Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2009;8:904-913.
31. Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J et al. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2009;52:4511-4523.
32. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009;16:1030-1039.
33. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-791. (Pubitemid 46192219)
34. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009;66:1326-1336.
35. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-388. (Pubitemid 44693472)
36. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001;15:515-522. (Pubitemid 32266720)
37. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007;104:6217-6222. (Pubitemid 47186075)
38. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-6110.
39. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25:1114-1120. (Pubitemid 46596764)
40. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006;1:1559-1582.